scholarly journals The long term prognostic significance of c-erbB-2 in primary breast cancer

1991 ◽  
Vol 63 (3) ◽  
pp. 447-450 ◽  
Author(s):  
J Winstanley ◽  
T Cooke ◽  
GD Murray ◽  
A Platt-Higgins ◽  
WD George ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Primary Breast Cancer ◽  
Prognostic Significance

Long-term prognostic significance of thymidine labelling index in primary breast cancer

1992 ◽  
Vol 28 (2-3) ◽  
pp. 424-426 ◽  
Author(s):  
T.G. Cooke ◽  
P.D. Stanton ◽  
G.D. Murray ◽  
J. Winstanley ◽  
R. Croton ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Primary Breast Cancer ◽  
Prognostic Significance ◽  
Labelling Index ◽  
Thymidine Labelling Index ◽  
Thymidine Labelling

scholarly journals Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing

2005 ◽  
Vol 7 (2) ◽  
Author(s):  
Marcus Schmidt ◽  
Barbara Lewark ◽  
Nikolai Kohlschmidt ◽  
Christiane Glawatz ◽  
Erik Steiner ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Significance ◽  
Node Negative ◽  
Node Negative Breast Cancer ◽  
Her 2

Pharmacokinetics (P) of tamoxifen (T) and related biological variables during long-term adjuvant T therapy in M0 primary breast cancer (M0PBC)

2001 ◽  
Vol 37 ◽  
pp. S67-S68
Author(s):  
G. Cartei ◽  
L. Franceschi ◽  
M. Furlanut ◽  
A. Bertolissi ◽  
P.G. Sala ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Primary Breast Cancer ◽  
Biological Variables

scholarly journals The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer

1997 ◽  
Vol 76 (4) ◽  
pp. 486-493 ◽  
Author(s):  
K Nooter ◽  
G Brutel de la Riviere ◽  
MP Look ◽  
KE van Wingerden ◽  
SC Henzen-Logmans ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Multidrug Resistance ◽  
Primary Breast Cancer ◽  
Prognostic Significance

Immunohistochemical study of p185 HER2 and DF3 in primary breast cancer and correlation with CA-15-3 serum tumor marker

2002 ◽  
Vol 12 (1) ◽  
pp. 74-79
Author(s):  
C Dimas ◽  
M Frangos-Plemenos ◽  
E Kouskouni ◽  
A Kondis-Pafitis
Keyword(s):  
Breast Cancer ◽  
Tumor Marker ◽  
Primary Breast Cancer ◽  
Immunohistochemical Study ◽  
Prognostic Significance ◽  
Growth Factor Receptor ◽  
Progesterone Receptors ◽  
Her2 Overexpression ◽  
Serum Tumor Marker ◽  
Degree Of Differentiation

Abstract.Dimas C, Frangos-Plemenos M, Kouskouni E, Kondis-Pafitis A. Immunohistochemical study of p185 HER2 and DF3 in primary breast cancer and correlation with CA-15-3 serum tumor marker.Human epidermal growth factor receptor 2 (p185 HER2) oncoprotein immunohistochemical expression and DF3 antigen distribution were evaluated in 129 patients with primary breast cancer. p185 HER2 overexpession was positively correlated with the degree of differentiation, metastatic disease, progesterone receptors, and cytoplasmic distribution of DF3 antigen. p185 HER2 overexpression had prognostic significance for the disease-free interval.

The Optimal Duration and Selection of Adjuvant Endocrine Therapy for Breast Cancer: How Long Is Enough?

2014 ◽  
pp. e16-e24 ◽  
Author(s):  
Ian E. Smith ◽  
Belinda Yeo ◽  
Gaia Schiavon
Keyword(s):  
Breast Cancer ◽  
Endocrine Therapy ◽  
Prognostic Significance ◽  
Indirect Evidence ◽  
Late Recurrence ◽  
Term Treatment ◽  
Adjuvant Endocrine Therapy ◽  
Risk Of Recurrence ◽  
Long Term Treatment

Women with estrogen receptor (ER)+ early breast cancer (BC) are at continuing risk of relapse up to at least 15 years after diagnosis, despite being on adjuvant endocrine therapy for approximately 5 years. Extended adjuvant endocrine therapy with an aromatase inhibitor (AI) after 5 years of tamoxifen further reduces the risk of recurrence in postmenopausal women. More recently, continuing tamoxifen for 10 years has also been shown to further reduce the risk of recurrence compared with 5 years. There are no direct comparative data on the relative merits of extended tamoxifen compared with an AI; indirect evidence suggests that an AI may have increased efficacy but a greater adverse effect on quality of life. Results are awaited on the need for continuing front-line adjuvant AIs for more than 5 years. The next challenge is to determine which patients will benefit from this long-term treatment. Currently, tumor size, nodal involvement, and gene expression profile as measured by the PAM50 Risk of Recurrence (ROR) score have all been shown to have prognostic significance for late recurrence beyond 5 years.

Sign in / Sign up

Export Citation Format

Share Document